Intramural Research

What this funds

Investigators and trainees in the NIAMS Intramural Research Program (IRP) conduct research and clinical trials on the immune system, bones, joints, muscles, and skin. They develop novel diagnostic tools to analyze these systems and treatments for the diseases that affect them. Offering insights into the mechanisms of disease: In a recent study, IRP scientists identified a pathway linking cardiovascular disease markers and disease activity in systemic lupus--findings that may eventually lead to therapeutic strategies.12 Another project utilized advanced sequencing techniques to identify gene variants associated with cold-induced hives and immune dysfunction.13 The novel approach utilized in this study may be applicable to and help improve understanding of other genetic immune disorders. Highlighting fundamental research across all health and disease areas: NIAMS IRP researchers also study how various proteins and enzymes repair and protect DNA from damaging events. Cells undergo tens of thousands of DNA-damaging events each day. Defects in repairing a certain type of damage (double-stranded breaks) can lead to genomic instability, contributing to cancer, genetic disorders, immunological diseases, and developmental defects. A protein complex called cohesin assists in preventing incorrect repair of the broken DNA strands. Recently, researchers found that the cohesin complex was modified (phosphorylated) upon DNA damage leading to enhanced repair speed, suggesting a more direct role for cohesin in DNA million or 4.1 percent compared with the FY 2026 Enacted level. Program plans for FY 2027 include continuing studies of basic, translational, and clinical research on the immune system, bones, joints, muscles, and skin. The program will continue long-term, high-risk research into the genetics and pathophysiology of human disease and the development of therapies for several serious disorders for which satisfactory treatments previously did not exist. The NIAMS IRP also is committed to its longstanding culture of mentoring trainees and providing a resource-rich Since the Institute's inception, the RMS budget has supported the scientific, administrative management, and information technology activities associated with NIAMS' day-to-day operations. For example, expansion of a pilot NIAMS AI chat tool was launched in FY 2024. Through RMS, NIAMS remains committed to advancing innovative research and supporting investigators through their portfolio supporting research in the areas of arthritis and rheumatic diseases, muscle and bone diseases, joint biology diseases and orthopedics, and skin diseases. million or 5.0 percent compared with the FY 2026 Enacted level. Activities for FY 2027 include implementing and evaluating progress toward supporting the institute's 10 articulated priorities from its Strategic Plan. Additionally, NIAMS intends to expand an FY 2024-2025 pilot effort exploring how AI can improve the efficiency of its business operations. National Institute of Arthritis and Musculoskeletal and Skin Diseases Detail of Full-Time Equivalent Employment (FTE) Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

Extracted from NIH - National Institute of Arthritis and Musculoskeletal and Skin Diseases, p. 10. Verbatim; nothing here is paraphrased.

Ask this budget line

Answers come from the figures on this page and nothing else. These dollars are parsed from Health & Human Services's Congressional Justification and are approximate — confirm anything that matters against the cited page.